2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 370

Double Positivity of RA Serologies More Prevalent Yet Associated with Clinical Response in Ethnic Minority Patients with Rheumatoid Arthritis
Abstract Number: 530

Downregulation of Microrna-183 in Sjogren’s Syndrome Minor Salivary Glands. Implications in Control of Ezrin Expression and Salivary Gland Function
Abstract Number: 2450

Downregulation of Mirna-196a and Its Downstream HOXC8 Target Gene in Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 285

Drug Safety in Treatment of Juvenile Idiopathic Arthritis (JIA): Biologic Therapy Compared with MTX
Abstract Number: 2776

Drug-Associated Cutaneous Vasculitis: Study of 239 Patients from a Single Referral Center
Abstract Number: 1686

DUAL Energy Computed Tomography for the Evaluation of Calcinosis in Systemic Sclerosis
Abstract Number: 2148

Dual Energy CT Scanning: Variable Sensitivity for Gout in Non-Tophaceous and Tophaceous Disease and in Individual Erosions
Abstract Number: 2820

Dual Role for B Cells in Promoting Bone Erosion in Rheumatoid Arthritis Via Effects on Osteoclast and Osteoblast Differentiation
Abstract Number: 2380

Durability of First Biologic Is Not Influenced By Initial/Early DAS28
Abstract Number: 219

DXA Body Composition, Sarcopenia and Knee and Hip Osteoarthritis: Results from the Khoala Cohort
Abstract Number: 1180

Dynamic Magnetic Resonance Imaging in the Assessment of the Response to Certolizumab Pegol in Rheumatoid Arthritis Patients: Results from a Phase IIIb Randomized Study
Abstract Number: 661

Dysfunction of Glycosphingolipid Metabolism in Lupus Nephritis
Abstract Number: 1040

Dysregulated Serum Interleukin 16 Concentration Associated with Clinical Disease Activity in Patients with Rheumatoid Arthritis Is Efficiently Corrected By Immunological Intervention
Abstract Number: 1957

Dysregulation of CC Chemokines at Microvascular Endothelial Cells of Blood and Lymphatic Vessels Under Inflammatory Conditions
Abstract Number: 2031

Early Adherence to Methotrexate in Rheumatoid Arthritis (RA) Is High: a Prospective Longitudinal Study of New Users

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].